Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Completed · Phase 2
Conditions studied: Congestive Heart Failure
In brief
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
Key facts
- Study ID
- NCT00043771
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 40
- Starts
- 2002-05-01
- Expected to finish
- 2002-09-01
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Central Cardiology Medical Clinic — Bakersfield, California, United States
- University of California-San Diego — San Diego, California, United States
- University of Miami/Jackson Memorial Hospital — Miami, Florida, United States
- Medical Research Institute — Slidell, Louisiana, United States
- Androscoggin Cardiology Associates — Auburn, Maine, United States
- University of Missouri-Kansas City School of Medicine — Kansas City, Missouri, United States
- Saint Louis University — St Louis, Missouri, United States
- Cardiology of Oklahoma — Tulsa, Oklahoma, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.